Kala Pharmaceuticals (KALA) Stocklytics Forecast

Kala Pharmaceuticals Inc (KALA) is a pharmaceutical company specializing in the development and commercialization of innovative therapies for ophthalmic diseases. With a focus on ocular surface diseases and disorders, Kala Pharmaceuticals aims to provide effective and convenient treatment options for patients. The company's flagship product is EYSUVIS, a corticosteroid designed to treat inflammation and pain associated with dry eye disease. EYSUVIS has shown promising results in clinical trials, with patients experiencing significant improvements in symptoms.

Looking ahead, Kala Pharmaceuticals Inc is poised for growth in the coming years. Analysts predict that the stock price of KALA will experience substantial increases, reaching a price target of $25 by 2023. This forecast is supported by the company's strong financial performance and the growing demand for its innovative products. In addition, KALA has received positive ratings from analysts, further bolstering confidence in the stock's potential. With its focus on addressing unmet needs in the ophthalmic market and a promising pipeline of products, Kala Pharmaceuticals Inc is indeed a good buy for investors looking to capitalize on the growing demand for ocular therapeutics.